Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 20 de 135
Filter
1.
Eur J Clin Microbiol Infect Dis ; 34(1): 177-186, 2015 Jan.
Article in English | MEDLINE | ID: mdl-25109886

ABSTRACT

Influenza and meteorological factors have been associated with increases in the incidence of invasive pneumococcal disease (IPD). However, scant data regarding the impact of influenza and the environment on the clinical presentation of IPD are available. An observational study of all adults hospitalized with IPD was performed between 1996 and 2012 in our hospital. The incidence of IPD correlated with the incidence rates of influenza and with environmental data. A negative binominal regression was used to assess the relationship between these factors. Clinical presentation of IPD during the influenza and non-influenza periods was compared. During the study, 1,150 episodes of IPD were diagnosed. After adjusting for confounding variables, factors correlating with the rates of IPD were the incidence of influenza infection (IRR 1.229, 95% CI 1.025-1.472) and the average ambient temperature (IRR 0.921, 95% CI 0.88-0.964). Patients with IPD during the influenza period had a worse respiratory status. A greater proportion of patients had respiratory failure (45.6% vs 52%, p = 0.032) and higher requirements for ICU admission (19.3% vs 24.7%, p = 0.018) and mechanical ventilation (11% vs 15.1%, p = 0.038). When we stratified by invasiveness of pneumococcal serotypes and the presence of comorbid conditions, the increase in the severity of clinical presentation was focused on healthy adults with IPD caused by nonhighly invasive serotypes. Beyond the increase in the burden of IPD associated with influenza, a more severe clinical pattern of pneumococcal disease was observed in the influenza period. This effect varied according to pneumococcal serotype, host comorbidities, and age.


Subject(s)
Climate , Influenza, Human/epidemiology , Pneumonia, Pneumococcal/epidemiology , Adult , Aged , Aged, 80 and over , Critical Care/statistics & numerical data , Female , Humans , Incidence , Male , Middle Aged , Pneumonia, Pneumococcal/complications , Pneumonia, Pneumococcal/pathology , Respiratory Insufficiency/epidemiology , Treatment Outcome
2.
Clin Microbiol Infect ; 20(11): 1205-10, 2014 Nov.
Article in English | MEDLINE | ID: mdl-24888250

ABSTRACT

Catheter-related bacteraemia (CRB) is a cause of death in hospitalized patients, and parenteral nutrition (PN) is a risk factor. We aim to describe the prognosis of PN-CRB and the impact of catheter extraction within 48 h from bacteraemia. All consecutive hospitalized adult patients with CRB (2007-2012) were prospectively enrolled. Factors associated with 30-day mortality were determined by logistic regression analysis. Among 847 episodes of CRB identified, 291 (34%) episodes were associated with short-term catheter use for PN. Cure was achieved in 236 (81%) episodes, 42 (14.5%) patients died within the first 30 days, 7 (2.5%) relapsed, and 6 (2%) had re-infection. On multivariate analysis, previous immunosuppressive therapy (OR 5.62; 95% CI 1.69-18.68; p 0.0048) and patient age (OR 1.05; 95% CI 1.02-1.07; p 0.0009) were predictors of 30-day mortality, whereas catheter removal within 48 h of bacteraemia onset (OR 0.26; 95% CI 0.12-0.58; p 0.0010) and adequate empirical antibiotic treatment (OR 0.36; 95% CI 0.17-0.77; p 0.0081) were protective factors. Incidence of PN-CRB decreased from 5.36 episodes/1000 days of PN in 2007 to 2.9 in 2012, yielding a 46.1% rate reduction (95% CI 15.7-65.5%), which may be attributable to implementation of a multifaceted prevention strategy. In conclusion, short-term PN-CRB accounted for one-third of all episodes of CRB in our setting, and 14.5% of patients died within 30 days following bacteraemia. Our findings suggest that prompt catheter removal and adequate empirical antibiotic treatment could be protective factors for 30-day mortality. Concomitantly with implementation of a multifaceted prevention strategy, PN-CRB incidence was reduced by half.


Subject(s)
Bacteremia/pathology , Catheter-Related Infections/pathology , Cross Infection/pathology , Parenteral Nutrition/adverse effects , Adult , Aged , Anti-Bacterial Agents/therapeutic use , Bacteremia/mortality , Catheter-Related Infections/mortality , Cohort Studies , Cross Infection/mortality , Female , Hospitals , Humans , Male , Middle Aged , Prognosis , Prospective Studies , Survival Analysis , Time Factors , Withholding Treatment
3.
Transpl Infect Dis ; 16(3): 387-96, 2014 Jun.
Article in English | MEDLINE | ID: mdl-24807640

ABSTRACT

BACKGROUND: Cytomegalovirus (CMV)-negative recipients of a graft from a CMV-positive donor (D+/R-) are at high risk of CMV disease. Current preventive strategies include universal prophylaxis (UP) and preemptive therapy (PT). However, the best strategy to prevent CMV disease and achieve better long-term outcomes remains a matter of debate. METHODS: We analyzed the incidence of CMV disease and long-term outcomes including graft dysfunction and patient mortality at 5 years after transplantation with both preventive strategies. High-risk (D+/R-) kidney and liver transplant recipients from the RESITRA cohort were included. RESULTS: Of 2410 kidney or liver transplant patients, 195 (8.3%) were D+/R-. The final cohort included 58 liver and 102 kidney recipients. UP was given in 92 patients and 68 received PT; 10.9% and 36.8% developed CMV disease, respectively (P < 0.01). The independent risk factors for CMV disease were PT strategy (hazard ratio [HR], 3.30; 95% confidence interval [CI], 1.6-6.9), kidney transplantation (HR, 3.8; 95% CI, 1.4-9.9), and cyclosporine immunosuppression (HR, 2.4; 95% CI, 1.2-4.7). PT strategy was also a risk factor for CMV disease in both liver transplantation (HR, 11.0; 95% CI, 1.2-98.7) and kidney transplantation (HR, 2.7; 95% CI, 1.3-6.0), independently. The development of CMV replication during the first 2 years after transplantation was a risk factor for graft dysfunction at 5 years after transplantation (odds ratio, 3.4; 95% CI, 1.3-9.0). Nevertheless, no significant differences were seen in either graft dysfunction or mortality between the 2 strategies. CONCLUSIONS: The study supports the benefit of the UP strategy to prevent CMV disease in D+/R- liver or kidney transplant patients. The development of CMV replication during the first 2 years after transplantation was associated with graft dysfunction at 5 years after transplantation.


Subject(s)
Cytomegalovirus Infections/etiology , Cytomegalovirus Infections/prevention & control , Ganciclovir/analogs & derivatives , Ganciclovir/pharmacology , Kidney Transplantation/adverse effects , Liver Transplantation/adverse effects , Adult , Antiviral Agents/pharmacology , Cohort Studies , Cytomegalovirus/physiology , Female , Humans , Immunosuppressive Agents , Male , Middle Aged , Risk Factors , Valganciclovir , Virus Replication , Young Adult
4.
Transpl Infect Dis ; 16(4): 532-8, 2014 Aug.
Article in English | MEDLINE | ID: mdl-24834833

ABSTRACT

INTRODUCTION: Infections caused by resistant gram-positive cocci (GPC), especially to glycopeptides, are difficult to treat in solid organ transplant (SOT) recipients as a result of lower effectiveness and high rates of renal impairment. The aim of this study was to evaluate the use of daptomycin in this population. METHODS: Over a 2-year period (March 2008-2010) in 9 Spanish centers, we enrolled all consecutive recipients who received daptomycin to treat GPC infection. The study included 43 patients, mainly liver and kidney transplant recipients. RESULTS: The most frequent infections were catheter-related bacteremia caused by coagulase-negative staphylococci (23.2%), skin infection caused by Staphylococcus aureus (11.5%), and intra-abdominal abscess caused by Enterococcus faecium (20.9%). The daily daptomycin dose was 6 mg/kg in 32 patients (74.4%). On day 7 of daptomycin treatment, median estimated area under the curve was 1251 µg/mL/h. At the end of follow-up, analytical parameters were similar to the values at the start of therapy. No changes were observed in tacrolimus levels. No patient required discontinuation of daptomycin because of adverse effects. Clinical success at treatment completion was achieved in 37 (86%) patients. Three patients died while on treatment with daptomycin. CONCLUSION: In summary, daptomycin was a safe and useful treatment for GPC infection in SOT recipients.


Subject(s)
Daptomycin/pharmacokinetics , Daptomycin/therapeutic use , Gram-Positive Bacterial Infections/drug therapy , Gram-Positive Cocci/isolation & purification , Organ Transplantation/adverse effects , Adolescent , Adult , Aged , Anti-Bacterial Agents/pharmacokinetics , Anti-Bacterial Agents/therapeutic use , Cohort Studies , Drug Resistance, Bacterial , Female , Gram-Positive Bacterial Infections/etiology , Humans , Male , Middle Aged , Young Adult
5.
J Infect ; 69(4): 387-95, 2014 Oct.
Article in English | MEDLINE | ID: mdl-24844823

ABSTRACT

OBJECTIVES: Aspergillus spp. can cause acute invasive disease in severely immunocompromised patients. Nonetheless, there are few reports of solid tumors complicated with subacute invasive pulmonary aspergillosis (subacute IPA). METHODS: Retrospective observational cohort study, performed in patients with primary lung cancer or secondary lung metastasis complicated with subacute IPA in three referral hospitals. RESULTS: From 2008 to 2011, 14 episodes of subacute IPA were diagnosed, including 11 (78.6%) probable and 3 proven (21.4%). Nine patients (64.3%) had primary lung cancer. Thirteen patients (92.9%) had more than one local or systemic predisposing factor for subacute IPA. No patient had previous fungal colonization. Aspergillus spp. was isolated in 6 specimens of bronchoalveolar lavage, 6 sputum, 2 biopsies, and 1 percutaneous lung puncture. At the time Aspergillus spp. was isolated, the most common radiologic findings on chest computed tomography (CT) were cavitary masses, and development or expansion of cavitation in existing masses or nodules (10/14, 71.4%). On CT follow-up, most patients (8/12, 66.7%) had new cavity formation or expansion of one or more existing cavities. All patients were treated with azoles and two underwent surgery. Ten (71.4%) patients died after Aspergillus spp. was detected (median time 73 days, IQR 33-243): 2 (20%) deaths were subacute IPA-attributable and 6 (60%) were related. CONCLUSIONS: Primary lung cancer and secondary lung metastasis seem to be triggering factors for Aspergillus spp. implantation, and predispose to subacute IPA. Once localized in the damaged lung, the mold can grow and cause or expand cavities. In lung cancer patients, Aspergillus spp. detection is associated with a very poor prognosis.


Subject(s)
Invasive Pulmonary Aspergillosis/pathology , Lung Neoplasms/microbiology , Adult , Aged , Aspergillus/isolation & purification , Cohort Studies , Female , Humans , Male , Middle Aged , Prognosis , Retrospective Studies , Risk Factors
6.
Clin Microbiol Infect ; 20 Suppl 7: 10-8, 2014 Sep.
Article in English | MEDLINE | ID: mdl-24476053

ABSTRACT

In the context of solid organ transplantation, screening of recipients and organ donors is crucial, and should be performed with great rigour to minimize the reactivation or the risk of transmission of certain infectious processes. This review aims to update understanding of the possible pathologies involved, as well as of emerging infections that, as a result of globalization, are gaining increasing prominence on a daily basis.


Subject(s)
Communicable Diseases/transmission , Disease Transmission, Infectious/prevention & control , Infection Control/methods , Mass Screening/methods , Organ Transplantation/adverse effects , Tissue Donors , Communicable Diseases, Emerging/prevention & control , Humans , Transplant Recipients
7.
Clin Microbiol Infect ; 20(7): 706-12, 2014 Jul.
Article in English | MEDLINE | ID: mdl-24329884

ABSTRACT

Chagas disease has been increasingly diagnosed in non-endemic countries. This is a prospective observational study performed at the Tropical Medicine Units of the International Health Program of the Catalan Health Institute, Barcelona (PROgrama de Salud Internacional del Instituto Catalán de la Salud, PROSICS Barcelona, Spain), that includes all patients with Chagas disease who attended from June 2007 to May 2012. Clinical and epidemiological data were collected. Overall, 1274 patients were included, the mean age of the patients was 37.7 years, 67.5% were women and 97% came from Bolivia. Thirteen patients had immunosuppressive conditions. The prevalence of cardiac involvement was 16.9%, lower than in previous studies performed in endemic areas (20-60%). Cardiac alterations were found in 33.8% of symptomatic and 14.1% of asymptomatic patients. The prevalence of digestive involvement was 14.8%. The rate of digestive involvement is very different among previous studies because of different diagnostic tools and strategies used. Barium enema alterations were found in 21.4% of symptomatic and 10.3% of asymptomatic patients, and oesophageal alterations were found in 3.7% of symptomatic and in 2.3% of asymptomatic patients. As shown in previous studies, Chagas disease in non-endemic countries affects younger patients and has lower morbidity.


Subject(s)
Chagas Disease/epidemiology , Chagas Disease/pathology , Trypanosoma cruzi/isolation & purification , Adolescent , Adult , Aged , Aged, 80 and over , Chagas Disease/parasitology , Digestive System Diseases/epidemiology , Digestive System Diseases/parasitology , Digestive System Diseases/pathology , Emigrants and Immigrants , Female , Heart Diseases/epidemiology , Heart Diseases/parasitology , Heart Diseases/pathology , Humans , Male , Middle Aged , Prospective Studies , Spain/epidemiology , Young Adult
8.
Pediatr Transplant ; 17(4): 403-6, 2013 Jun.
Article in English | MEDLINE | ID: mdl-23692602

ABSTRACT

The aim of this study was to assess the immunogenicity of a vaccine against this virus in a prospective cohort of transplanted pediatric patients without previous influenza infection who received one dose of MF59®-adjuvanted pandemic H1N1/2009 vaccine. Seventeen patients who were being regularly followed up at the Outpatient Clinic of the Children's Transplant Unit (liver and kidney transplantation) in Hospital Universitari Vall d'Hebron (Barcelona) were included. Seroconversion was demonstrated in 15 of 17 (88.2%) vaccinated children. There were no rejection episodes or major adverse events. The MF59(®) -adjuvanted pandemic H1N1/2009 vaccine was safe and elicited an adequate response.


Subject(s)
Influenza A Virus, H1N1 Subtype , Influenza Vaccines/therapeutic use , Influenza, Human/prevention & control , Kidney Transplantation , Liver Transplantation , Adjuvants, Immunologic/administration & dosage , Adolescent , Child , Child, Preschool , Cohort Studies , Female , Humans , Immunosuppressive Agents/adverse effects , Influenza Vaccines/adverse effects , Influenza Vaccines/immunology , Male , Patient Safety , Polysorbates/administration & dosage , Prospective Studies , Squalene/administration & dosage
9.
Clin Microbiol Infect ; 19(4): 385-91, 2013 Apr.
Article in English | MEDLINE | ID: mdl-22583156

ABSTRACT

The introduction of the 7-valent pneumococcal conjugate vaccine in children has led to a change in the pattern of pneumococcal serotypes causing pneumococcal disease. The aim of this study was to compare the clinical presentation and outcome of invasive pneumococcal pneumonia (IPP) in adults between the pre and post-vaccine era. We have conducted an observational study of all adults hospitalized with IPP, from 1996 to 2001 (pre-vaccine period), and from 2005 to 2009 (post-vaccine period). Incidence, serotype distribution and clinical data were compared between both periods. A total of 653 episodes of IPP were diagnosed. The overall incidence of IPP increased from 14.2 to 17.9 cases per 100 000 population-year (p 0.003). In the post-vaccine period IPP caused by vaccine serotypes decreased (-36%; 95% CI, -52 to -15) while IPP caused by non-vaccine serotypes increased (71%; 95% CI, 41-106). IPP in the post-vaccine period was associated with higher rates of septic shock (19.1% vs. 31.1%, p <0.001). Among patients aged 50-65 years there was a trend towards a greater proportion of case-fatalities (11.6-23.5%, p 0.087). Independent risk factors for septic shock were IPP caused by serotype 3 (OR 2.38; 95% CI, 1.16-4.87) and serotype 19A (OR 6.47, 95% CI, 1.55-27). Serotype 1 was associated with a lower risk of death (OR 0.1; 95% CI, 0.01-0.78). In conclusion, the incidence of IPP in the post-vaccine period has increased in our setting, it is caused mainly by non-vaccine serotypes and it is associated with higher rates of septic shock.


Subject(s)
Pneumococcal Vaccines/immunology , Pneumonia, Pneumococcal/epidemiology , Pneumonia, Pneumococcal/microbiology , Shock, Septic/epidemiology , Shock, Septic/microbiology , Streptococcus pneumoniae/classification , Streptococcus pneumoniae/isolation & purification , Adolescent , Adult , Aged , Aged, 80 and over , Female , Heptavalent Pneumococcal Conjugate Vaccine , Hospitalization , Humans , Incidence , Male , Middle Aged , Pneumococcal Vaccines/administration & dosage , Pneumonia, Pneumococcal/complications , Pneumonia, Pneumococcal/pathology , Serotyping , Shock, Septic/pathology , Treatment Outcome , Vaccination/statistics & numerical data , Young Adult
10.
HIV Med ; 14(1): 21-30, 2013 Jan.
Article in English | MEDLINE | ID: mdl-22726389

ABSTRACT

BACKGROUND: Despite the reported decrease in the incidence and mortality rates of central nervous system (CNS) infections after the introduction of highly active antiretroviral therapy (HAART), few studies have focused on the global incidence and the relationship of these diseases with immune reconstitution inflammatory syndrome (IRIS) in the developed world. METHODS: A descriptive cohort study of all consecutive adult HIV-infected patients with CNS opportunistic infections diagnosed between 2000 and 2010 in a tertiary hospital in Spain was carried out. Demographic, clinical, laboratory, and microbiological data were recorded. Patients were followed up until death or loss to follow-up or until 30 July 2011, when the study finished. The significance of differences in the incidence rate between early and late HAART periods was determined using the Mantel-Haenszel test. Survival distribution was estimated using the Kaplan-Meier method. RESULTS: A total of 110 cases of CNS infections were diagnosed. The incidence of CNS opportunistic infections decreased from 9 cases per 1000 HIV-infected patients per year in the early HAART period to 3.8 in the late HAART period (P = 0.04). Overall, the estimated mean survival time was 58.8 months (95% confidence interval 47.1-70.6 months). Of the 110 patients, 18 (16.4%) met the criteria of IRIS, 10 (55.6%) were paradoxical and eight (44.4%) were unmasking. IRIS was not associated with a higher mortality rate. CONCLUSIONS: The annual incidence of CNS infections decreased progressively during the period of study. The mortality rate associated with these diseases remains high despite HAART. The development of IRIS associated with neurological infections had no influence on prognosis.


Subject(s)
Antiretroviral Therapy, Highly Active/adverse effects , Central Nervous System Diseases/epidemiology , HIV Infections/drug therapy , HIV-1 , Immune Reconstitution Inflammatory Syndrome/epidemiology , AIDS-Related Opportunistic Infections/epidemiology , AIDS-Related Opportunistic Infections/etiology , Adult , Central Nervous System Diseases/etiology , Cohort Studies , Female , HIV Infections/complications , Humans , Immune Reconstitution Inflammatory Syndrome/etiology , Incidence , Male , Middle Aged , Spain/epidemiology
11.
Clin Microbiol Infect ; 18(12): E522-30, 2012 Dec.
Article in English | MEDLINE | ID: mdl-23077981

ABSTRACT

The aim of this study was to describe the immediate and long-term prognosis of a contemporary cohort of patients with left-sided infective endocarditis (LSIE). A prospective observational cohort study was conducted in a referral centre. Between January 2000 and December 2011, all consecutive adult patients with LSIE were followed-up until death, relapse, recurrence, need for late surgery, or last control. During the active phase of IE, 174 of 438 patients underwent surgery (40% overall; 43% native valve (NVIE), 30% prosthetic valve (PVIE)) and 125 died (29% overall; 26% NVIE, 39% PVIE). The median follow-up in survivors was 3.2 years (interquartile range (IQR) 1.0-6.0 years). Relapses occurred in seven patients (2.2%; 95% CI, 1.1-4.5) and recurrences in eight (2.6%; 95% CI, 1.3-5.0), with an incidence density of 0.0067 per patient-year (95% CI, 0.0029-0.0133) and high mortality (75% of recurrences). Only four of 130 survivors (3.1%; 95% CI, 1.2-7.6) who were treated surgically during the active phase of the disease, and 14/183 (7.7%; 95% CI, 4.6-12.4) of those not undergoing surgery needed operation during follow-up (p 0.09). In the 313 survivors, actuarial survival was 86% at 1 year (87% NVIE, 83% PVIE), 79% at 2 years (81% NVIE, 72% PVIE) and 68% at 5 years (71% NVIE, 57% PVIE). At 1 year, 115 of 397 patients (29.0%; 95% CI, 24.7-33.6) remained alive, with no surgery requirement, relapse or recurrence. LSIE is associated with considerable in-hospital and long-term mortality, especially PVIE. However, relapses, recurrences and the need for late surgery are uncommon.


Subject(s)
Endocarditis/epidemiology , Adolescent , Adult , Aged , Cohort Studies , Endocarditis/surgery , Female , Humans , Male , Middle Aged , Prospective Studies , Recurrence , Survival Analysis , Tertiary Care Centers , Treatment Outcome , Young Adult
12.
Transpl Infect Dis ; 14(6): 584-8, 2012 Dec.
Article in English | MEDLINE | ID: mdl-22998763

ABSTRACT

AIM AND METHOD: The aim of this study was to describe the clinical characteristics and outcome of pandemic influenza A H1N1/2009 (pH1N1) infection, in a retrospective cohort of pediatric patients with kidney and/or liver transplant and confirmed pH1N1 infection from June to December 2009, diagnosed in 2 Spanish teaching hospitals. RESULTS: Forty-nine patients were included. Pneumonia was diagnosed in 4 patients (8.2%), and 3 of them required respiratory support. There were no related deaths. CONCLUSION: Antiviral treatment within 48 h was associated with a lower likelihood of pneumonia (0/38, 0%) than treatment started after 48 h (4/11, 36.3%) (P < 0.01).


Subject(s)
Antiviral Agents/therapeutic use , Influenza A Virus, H1N1 Subtype , Influenza, Human/prevention & control , Kidney Transplantation/adverse effects , Liver Transplantation/adverse effects , Adolescent , Child , Female , Humans , Immunocompromised Host , Influenza, Human/epidemiology , Influenza, Human/virology , Male , Pandemics , Pneumonia/etiology , Retrospective Studies , Spain/epidemiology
13.
Med Mycol ; 49(5): 525-9, 2011 Jul.
Article in English | MEDLINE | ID: mdl-21198347

ABSTRACT

Two new species related to Candida glabrata, i.e., Candida nivariensis and Candida bracarensis, have been proposed. The occurrence of these species among isolates collected in a Spanish mycology reference laboratory in 2008-2009 was reviewed. In addition, strains recovered as part of an active population-based surveillance of candidemia conducted in Barcelona between 2002 and 2003 were also analyzed. Among 143 clinical isolates received in 2008-2009, three (2%) were identified as C. bracarensis and none as C. nivariensis through sequencing of their ribosomal DNA. Of the 31 strains initially identified as C. glabrata in the 2002-2003 population-based study (0.38 cases/100,000 population), none were found to belong to these related new species. Results from in vitro susceptibility studies of C. bracarensis isolates were comparable to those found with C. glabrata. Since new and cryptic species have been described, periodic surveillance including the use of molecular identification methods seems to be necessary in order to determine their frequency, geographical distribution and susceptibility profile.


Subject(s)
Candida/classification , Candida/isolation & purification , Candidemia/epidemiology , Candidemia/microbiology , Antifungal Agents/pharmacology , Candida/drug effects , Candida/genetics , DNA, Fungal/chemistry , DNA, Fungal/genetics , DNA, Ribosomal Spacer/chemistry , DNA, Ribosomal Spacer/genetics , Microbial Sensitivity Tests , Prevalence , Sequence Analysis, DNA , Spain/epidemiology
14.
Clin Microbiol Infect ; 17(5): 769-75, 2011 May.
Article in English | MEDLINE | ID: mdl-20636419

ABSTRACT

The aims of this study were to compare the characteristics of adult patients with left-sided infective endocarditis (LSIE) diagnosed and treated in a tertiary-care hospital with those of patients referred from a second-level community hospital, and to establish the accuracy of diagnosis and adequacy of treatment in referred patients and the influence of this factor on outcome. A prospective observational cohort study was conducted at Hospital Universitari Vall d'Hebron, a 1000-bed teaching hospital in Barcelona (Spain) and a referral centre for cardiac surgery. One hundred and fourteen of 337 (34%) episodes of LSIE treated in our hospital occurred in transferred patients. As compared with patients diagnosed in our hospital, transferred patients acquired LSIE within the healthcare system less often (16.7% vs. 38.1%, p <0.001), were in better health (Charlson index 3 (interquartile range (IQR)) 1-4) vs. 4 (IQR 2-6), p <0.001), had more complications (94.7% vs. 78.9%, p <0.001), underwent more operations (69.3% vs. 22.1%, p <0.001), and experienced similar mortality (22.8% vs. 31.4%, p 0.100). Only 52 of 114 (45.6%) referred patients received an antimicrobial regimen included in the American, European or Spanish guidelines at the hospital of origin. After adjustment for congestive heart failure and staphylococcal infection in multivariate logistic regression, inadequate or no antimicrobial treatment at origin was a risk factor for in-hospital mortality (OR 3.3, 95% CI 1.1-10.0, p 0.030). Errors in the initial antimicrobial treatment prescribed for LSIE are associated with greater mortality.


Subject(s)
Anti-Bacterial Agents/therapeutic use , Endocarditis/diagnosis , Hospital Mortality/trends , Adult , Aged , Aged, 80 and over , Clinical Protocols , Cohort Studies , Diagnostic Errors , Endocarditis/drug therapy , Endocarditis/mortality , Female , Guidelines as Topic , Health Facility Size , Hospitalization , Hospitals, Community , Hospitals, Teaching , Hospitals, University , Humans , Male , Middle Aged , Prognosis , Prospective Studies
15.
Clin Microbiol Infect ; 16(11): 1676-82, 2010 Nov.
Article in English | MEDLINE | ID: mdl-20219079

ABSTRACT

Although Candida albicans (CA) is the most common cause of Candida bloodstream infections (BSIs), recent studies have observed an increasing percentage of candidaemias caused by non-albicans Candida species (NAC). In the present study, we attempted to identify the predictors of candidaemia due to NAC compared to CA. We analyzed data from an active population-based surveillance in Barcelona (Spain) from January 2002 to December 2003. Factors associated with NAC fungaemia were determined by multivariate analysis. A total of 339 episodes of Candida BSI, in 336 patients (median age 63 years, interquartile range: 41-72 years), were included. CA was the most commonly isolated (52%), followed by Candida parapsilosis (23%), Candida tropicalis (10%), Candida glabrata (8.6%), Candida krusei (3.4%) and other NAC spp. (3%).Overall, 48% of cases were due to NAC spp. Multivariate logistic regression analysis identified factors associated with a risk of BSI due to NAC spp.: having received a haematologic transplant (OR 10.8; 95% CI 1.31-90.01; p 0.027), previous fluconazole exposure (OR 4.47; 95% CI 2.12-9.43; p <0.001) and neonatal age (OR 4.42; 95% CI 1.63-12.04; p 0.004). Conversely, previous CA colonization (OR 0.33; 95% CI 0.19-0.57; p 0.001) and previous antibiotic use (OR 0.42; 95% CI 0.21-0.85; p 0.017) were associated with CA fungaemia compared to NAC. In conclusion, NAC candidaemia comprised 48% of cases in our series. Predictors of NAC include having received a haematologic transplant, neonatal age and previous fluconazole use.


Subject(s)
Candida/classification , Candidemia/epidemiology , Candidemia/microbiology , Adult , Age Factors , Aged , Antifungal Agents/administration & dosage , Cross Infection/epidemiology , Cross Infection/microbiology , Female , Fluconazole/adverse effects , Fluconazole/therapeutic use , Humans , Infant, Newborn , Male , Middle Aged , Population Surveillance , Regression Analysis , Risk Factors , Spain/epidemiology , Transfusion Reaction
16.
HIV Med ; 10(6): 356-63, 2009 Jul.
Article in English | MEDLINE | ID: mdl-19490180

ABSTRACT

BACKGROUND: Recent studies in hospitalized patients with community-acquired pneumonia have found a lower risk of bacteraemia and better clinical outcomes in patients who had previously received the 23-valent pneumococcal polysaccharide vaccine (PPV) in comparison with unvaccinated individuals. The aim of this study was to assess the influence of prior PPV on clinical outcomes in HIV-infected adult patients hospitalized with invasive pneumococcal disease (IPD). METHODS: This was an observational study of all consecutive HIV-infected adults hospitalized with IPD from January 1996 to October 2007 in three hospitals in Spain. Baseline characteristics and clinical outcome-related variables were compared according to prior PPV vaccination status. RESULTS: A total of 162 episodes of IPD were studied. In 23 of these (14.2%), patients had previously received PPV. In both vaccinated and unvaccinated patients, most of the causal serotypes were included in the 23-valent PPV (76.9% and 84.1%, respectively). Overall, 25 patients (15.4%) died during hospitalization, 21 patients (13%) required admission to an intensive care unit (ICU) and 34 patients (21%) reached the composite outcome of death and/or admission to the ICU. None of the 23 patients who had previously received PPV died or required ICU admission, in comparison with 25 (18%; P=0.026) and 21 (15.1%; P=0.046), respectively, of the unvaccinated patients. The length of hospital stay for vaccinated patients was significantly shorter (8.48 vs. 13.27 days; P=0.011). CONCLUSIONS: Although 23-valent PPV failed to prevent IPD in some HIV-infected patients, vaccination produced beneficial effects on clinical outcomes by decreasing illness severity and mortality related to IPD.


Subject(s)
AIDS-Related Opportunistic Infections/prevention & control , HIV-1 , Pneumococcal Vaccines/therapeutic use , Pneumonia/prevention & control , AIDS-Related Opportunistic Infections/immunology , Adult , Community-Acquired Infections/immunology , Community-Acquired Infections/prevention & control , Female , Hospitalization/statistics & numerical data , Humans , Male , Pneumonia/immunology , Spain/epidemiology
17.
Transplant Proc ; 41(3): 1038-40, 2009 Apr.
Article in English | MEDLINE | ID: mdl-19376420

ABSTRACT

UNLABELLED: Preemptive therapy with ganciclovir has been recommended in the pediatric liver transplant strategy to avoid the development of posttransplant lymphoproliferative disorder (PTLD) from an high Epstein-Barr virus (EBV) is detected. We sought viral load to analyze the response to preemptive therapy with valganciclovir (VGC) in children with liver transplantations and an high quantitative EBV-PCR. METHODS: From June 2005 to December 2007, we tested 979 EBV-PCR among 80 pediatric liver transplant recipients, from those 21/80 PCR were tested from the date of transplantation and 59/80 belonged to the historical cohort (7/59 had a prior history of PTLD). Patients were divided into 2 groups depending upon whether they did (n = 22) or did not (n = 19) receive VGC treatment. The response to VGC was considered complete, if the PCR was negative at 30 and 60 days of treatment; and partial, when the PCR decreased at least 50%. Ganciclovir blood levels tested in 109 cases instances and correlated with the EBV-PCR. RESULTS: A total of 369 (33%) positive PCR were detected in 36/80 patients (mean, 75,000 copies; range = 5000-4,200,000). Among the 22 episodes treated for 30 days, 34% showed complete responses, 41%, partial, and 23%, no response. Among the non-treated group the rates were 6%, 25%, and 68%, respectively (P = .01). However, no differences were observed among those episodes treated for 60 days. At the administered doses, hardly any patient reached the recommended ganciclovir therapeutic level at 2 hours (6 micro/mL). However, the mean PCR was lower when the ganciclovir levels were greater than 4 mg/L when compared with lower levels (P = .03). CONCLUSION: After 30 days of treatment there was a response to VGC in the EBV viral load. There was high interpatient variability of ganciclovir serum concentrations, suggesting the need for pharmacokinetic monitoring to optimize treatment. There was a relationship between the concentration of ganciclovir and the EBV viral load.


Subject(s)
Antiviral Agents/therapeutic use , Epstein-Barr Virus Infections/drug therapy , Ganciclovir/analogs & derivatives , Herpesvirus 4, Human/genetics , Liver Transplantation/methods , Child , Cohort Studies , Epstein-Barr Virus Infections/genetics , Ganciclovir/therapeutic use , Genome, Viral/drug effects , Herpesvirus 4, Human/drug effects , Humans , Liver Transplantation/adverse effects , Polymerase Chain Reaction/drug effects , Polymerase Chain Reaction/methods , Retrospective Studies , Valganciclovir , Viral Load
18.
Int J STD AIDS ; 20(3): 193-5, 2009 Mar.
Article in English | MEDLINE | ID: mdl-19255269

ABSTRACT

It can be difficult to establish the clinical significance of the isolation of non-tuberculous mycobacteria (NTM) from the sputum of HIV-infected patients. In this observational study, we have investigated factors associated with having NTM infection. During the period of the study, 10 patients had NTM infection and 14 had NTM colonization. Factors associated with having NTM infections were: CD4 lymphocyte count <50 cells/mL (odds ratio [OR] 10; 95% confidence interval [CI] 1.4-69.3), haemoglobin <11 g/dL (OR 7.2; 95% CI 1.08-47.9), weight loss (OR 9; 95% CI 1.3-63.9), duration of symptoms for more than a month (OR 54; 95% CI 4.2-692.5), the presence of acid fast bacilli (AFB) in sputum (OR 30.3; 95% CI 2.6-348.9) and repeated positive NTM cultures in other sputum samples (OR 4.3; 95% CI 1.6-11.7). In conclusion, we must suspect NTM infection in patients with long-standing symptoms, anaemia, low CD4 lymphocyte count, several positive sputum cultures and when AFB are seen.


Subject(s)
AIDS-Related Opportunistic Infections/epidemiology , Mycobacterium Infections, Nontuberculous/epidemiology , Mycobacterium avium-intracellulare Infection/epidemiology , Nontuberculous Mycobacteria/isolation & purification , Sputum/microbiology , AIDS-Related Opportunistic Infections/microbiology , Adult , CD4 Lymphocyte Count , Female , Hemoglobins/analysis , Humans , Male , Middle Aged , Mycobacterium Infections, Nontuberculous/microbiology , Mycobacterium avium Complex/isolation & purification , Mycobacterium avium-intracellulare Infection/microbiology , Mycobacterium kansasii/isolation & purification , Mycobacterium xenopi/isolation & purification , Statistics, Nonparametric , Weight Loss
19.
Eur J Clin Microbiol Infect Dis ; 28(4): 317-23, 2009 Apr.
Article in English | MEDLINE | ID: mdl-18797941

ABSTRACT

The purpose of this paper was to review our clinical experience in patients with osteomyelitis (OM) of the jaw, focusing on aspects of antimicrobial resistance. A retrospective review of the medical records of adult patients with jaw OM was carried out. Among 46 cases of jaw OM, the cause was odontogenic in 32 (seven had recent dental implants and four bisphosphonate osteonecrosis), postoperative/post-traumatic in eight, and secondary to osteoradionecrosis in six. Clinical features were chronic in 91.3%. The infection was polymicrobial in 24/41 (65.9%). Viridans streptococci were the most commonly isolated agents. Among 26 viridans streptococci tested, 81% were susceptible to penicillin and 96% to fluorquinolones, but only 11.5% to clindamycin. Overall, 35/38 (92.1%) had at least one clindamycin-resistant isolate. Appropriate antibiotics were administered for a mean of 5.8 +/- 3.2 months. Beta-lactams were used in 19 cases and fluorquinolones in 14. Among 39 cases with long-term follow-up, only two relapsed. Currently, jaw OM is commonly related to osteoradionecrosis, dental implants, and bisphosphonates. In patients with prior antibiotics exposure, a high percentage of infections were caused by clindamycin-resistant microorganisms, thus, beta-lactams should be the antibiotic of choice. In penicillin-allergic cases, the new fluorquinolones, probably in combination with rifampin and/or clindamycin, could be a promising alternative.


Subject(s)
Clindamycin/pharmacology , Gram-Negative Bacterial Infections , Gram-Positive Bacterial Infections , Jaw Diseases/microbiology , Osteomyelitis/microbiology , Adolescent , Adult , Aged , Aged, 80 and over , Anti-Bacterial Agents/pharmacology , Anti-Bacterial Agents/therapeutic use , Clindamycin/therapeutic use , Dental Implants/microbiology , Diphosphonates , Drug Resistance, Bacterial/drug effects , Female , Gram-Negative Bacterial Infections/drug therapy , Gram-Negative Bacterial Infections/microbiology , Gram-Positive Bacterial Infections/drug therapy , Gram-Positive Bacterial Infections/microbiology , Humans , Jaw Diseases/diagnostic imaging , Jaw Diseases/drug therapy , Male , Middle Aged , Osteomyelitis/diagnostic imaging , Osteomyelitis/drug therapy , Osteonecrosis/microbiology , Radiography , Retrospective Studies , Risk Factors , Streptococcal Infections/drug therapy , Streptococcal Infections/microbiology , Viridans Streptococci/drug effects
20.
J Neurovirol ; 14(6): 474-9, 2008 Nov.
Article in English | MEDLINE | ID: mdl-19037815

ABSTRACT

The objective of this study is to describe a series of cases of severe meningitis caused by human immunodeficiency virus type 1 (HIV-1) occurring during primary infection or after antiretroviral treatment interruption. In an observational cohort study, 13 patients with clinical diagnosis of meningitis or meningoencephalitis were reviewed. Ten cases occurred during primary HIV-1 infection and 3 after antiretroviral therapy (ART) withdrawal. Demographic parameters, clinical presentation and outcome, and laboratory and cerebrospinal fluid (CSF) parameters were recorded. The risk factor for HIV-1 infection acquisition was sexual transmission in all cases. The most frequent systemic symptoms were fever (12/13) and headeache (9/13). Among neurologic symptoms, focal signs appeared in seven patients (53.8%), confusion in six (46.2%), and agitation in five (38.5%). The median CD4 cell count was 434 cells/mm3. In all cases, CSF was a clear lymphocytaire fluid with normal glucose levels. Cranial computerized tomography was performed in seven patients, with a normal result in all of them; brain magnetic resonance in eight patients was normal in five cases and showing cortical atrophy, limbic encephalitis, and leptomeningeal enhancement in one patient each. The electroencephalographs (EEG) just showed diffuse dysfunction in three cases. ART was started in 11 patients. HIV RNA load at 12 months was <50 copies/ml in all treated patients. The 13 patients recovered without neurologic sequela. Meningitis or meningoencephalitis during primary HIV-1 infection or after ART cessation are unusual but sometimes a life-threatening manifestation. Although all patients tend to recover and the necessity of ART is not well established, some data suggest its potential benefit in these patients.


Subject(s)
HIV Infections/complications , HIV-1 , Meningitis, Viral/diagnosis , Meningoencephalitis/diagnosis , Meningoencephalitis/virology , Acute Disease , Adult , Anti-Retroviral Agents/therapeutic use , CD4 Lymphocyte Count , Cerebral Cortex/physiopathology , Cohort Studies , Confusion/diagnosis , Confusion/virology , Female , Fever/diagnosis , Fever/virology , HIV Infections/drug therapy , Headache/diagnosis , Headache/virology , Humans , Male , Meningitis, Viral/physiopathology , Meningoencephalitis/physiopathology , Middle Aged , Psychomotor Agitation/diagnosis , Psychomotor Agitation/virology , Retrospective Studies , Viral Load , Withholding Treatment
SELECTION OF CITATIONS
SEARCH DETAIL
...